NCT04940208

Chronic Pain in COVID-19 Patients Discharged From Intensive Care Unit

Completed Last updated 2 February 2022

What this trial tests

trial testing Pain and neuropsychological questionnaires in COVID-19 Pandemic in 143 participants. Completed in 1 February 2022.

Timeline

11 January 2021

Primary endpoint
1 January 2022

1 February 2022

Quick facts

Lead sponsor	Mikhail Dziadzko, MD, PhD
Status	Completed
Study type	OBSERVATIONAL
Enrollment	143
Start date	11 January 2021
Primary completion	1 January 2022
Estimated completion	1 February 2022
Sites	3 locations across France

Drugs / interventions tested

• Pain and neuropsychological questionnaires
• Quantitative Sensory testing

Conditions studied

• COVID-19 Pandemic — all drugs for COVID-19 Pandemic →
• ICU — all drugs for ICU →
• Pain, Chronic — all drugs for Pain, Chronic →
• Post Intensive Care Unit Syndrome — all drugs for Post Intensive Care Unit Syndrome →

Sponsor

Mikhail Dziadzko, MD, PhD

Who can join

18 and older, any sex, with COVID-19 Pandemic or ICU. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

More than six million French were affected by SARS-COV2 epidemic. About 20% of infected peoples were hospitalized, and about 5% were admitted to the intensive care units (ICU) for severe SARS-COV2 acute respiratory distress syndrome (ARDS) management.

A spectrum of neuropsychiatric sequelae, specific for the ICU exposure, was already described, including post-intensive care syndrome and persistent pain.

A growing body of evidence suggests the impact of SARS-COV2 exposure on the occurrence of neurological disorders and chronic pain syndrome development in COVID-19 patients.

Taking together, one can expect a large number of patients discharged from ICU after severe COVID-19 with high prevalence of persistent pain and psychological disorders. To date, no study has evaluated neither the incidence of persistant pains in ICU COVID-19 survivors, nor pain phenotypes.

The knowledge of such data is crucial in order to anticipate the management of such patients by specialized pain team, and to quantify the possible incurred burden of care.

Our study aims to evaluate the incidence of pain, pain localization and severity, associated pain-related psychological disorders, and to perform quantitative sensory testing in severe COVID-19 patients, admitted to the ICU for more than 48 hours and successfully discharged home during the first French pandemic wave.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Chronic pain characteristics in COVID-19 survivors after an ICU stay. A cross-sectional study.
   Martinez V, Dziadzko M, Tamayo J, Schitter S, et al · · 2023 · cited 8× · PMID 37356618 · DOI 10.1016/j.accpm.2023.101267